DexCom - DXCM Stock Forecast, Price & News

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Price Performance

DXCM Stock opened at $91.40 on Tuesday. DexCom has a 1 year low of $66.89 and a 1 year high of $164.86. The company has a market cap of $35.88 billion, a P/E ratio of 190.42, a PEG ratio of 3.57 and a beta of 1.03. The firm has a 50-day moving average of $78.13 and a 200 day moving average of $95.12. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.72 and a quick ratio of 4.30.

DexCom (NASDAQ:DXCM - Get Rating) last released its quarterly earnings results on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.02). DexCom had a return on equity of 11.79% and a net margin of 7.47%. The company had revenue of $696.20 million during the quarter, compared to the consensus estimate of $709.33 million. During the same period in the previous year, the company earned $0.19 earnings per share. DexCom's quarterly revenue was up 17.0% on a year-over-year basis. On average, sell-side analysts forecast that DexCom will post 0.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Citigroup cut their target price on shares of DexCom from $105.00 to $100.00 in a research report on Friday, July 29th. BTIG Research cut their target price on shares of DexCom from $135.00 to $105.00 and set a "buy" rating for the company in a research report on Friday, June 24th. Raymond James cut their target price on shares of DexCom from $134.50 to $121.50 in a research report on Friday, April 29th. Canaccord Genuity Group cut their target price on shares of DexCom from $131.25 to $125.00 in a research report on Friday, April 29th. Finally, Piper Sandler cut their price target on shares of DexCom from $120.00 to $110.00 and set an "overweight" rating for the company in a research report on Friday, July 29th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $115.23.

Insider Buying and Selling

In other DexCom news, Director Steven Robert Pacelli sold 1,000 shares of the firm's stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $83.07, for a total transaction of $83,070.00. Following the completion of the transaction, the director now owns 138,700 shares of the company's stock, valued at $11,521,809. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other DexCom news, CFO Jereme M. Sylvain sold 600 shares of the firm's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $301.57, for a total transaction of $180,942.00. Following the completion of the transaction, the chief financial officer now owns 17,408 shares of the company's stock, valued at $5,249,730.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven Robert Pacelli sold 1,000 shares of the firm's stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $83.07, for a total transaction of $83,070.00. Following the transaction, the director now directly owns 138,700 shares of the company's stock, valued at approximately $11,521,809. The disclosure for this sale can be found here. Insiders sold a total of 2,850 shares of company stock valued at $410,645 over the last three months. Corporate insiders own 0.41% of the company's stock.